đïž Beyond Skin Deep & Gut Feelings â Part 2: When the Gut and Skin Share the Treatment Plan One patient. Two organ systems. And suddenly, choosing a biologic gets a whole lot more interesting. đ In Part 2 of our Derm Ă GI crossover, podcast Faculty members dermatologist Dr. Perry Grewal and gastroenterologist Dr. Jesse Siffledeen move from diagnosis into the real-world treatment decisions that happen when psoriasis and inflammatory bowel disease collide. PRO-TIPS COVERED: How do you practically choose one therapy when youâre treating two inflammatory diseases? When might suspected IBD steer a dermatologist away from an IL-17 inhibitor? What happens when the dose needed for Crohnâs disease doesnât match the dose used for psoriasis? And when one drug isnât enough, is dual advanced therapy the next frontierâor an insurance headache waiting to happen? đ The conversation also digs into the very different therapeutic ceilings in dermatology and gastroenterology, including emerging data in perianal Crohnâs disease, the challenge of achieving true mucosal healing, and why GI may still be chasing remission rates that dermatology has already learned to expect from modern psoriasis therapy. It gets practical: Who owns the prescription? Who takes the lead when one organ system flares? How much communication is really needed between specialists? And where do vaccinations fit when advanced therapy needs to start quickly? From IL-23s vs IL-17s to biologic dosing, multidisciplinary care, vaccine timing and the occasional therapeutic turf war, this is where âshared careâ leaves the PowerPoint slide and enters actual clinical practice. 𧩠đŻ Learning Objectives After listening to this episode, participants should be able to: 1. Compare key clinical factors that influence advanced therapy selection in patients with psoriasis and coexisting or suspected inflammatory bowel disease. 2. Explain how IL-17, IL-23 and TNF-targeted therapies may be approached differently when Crohnâs disease, fistulizing disease or possible IBD is part of the clinical picture. 3. Discuss real-world challenges in multidisciplinary treatment, including differing doses across indications, prescription ownership, reimbursement barriers and situations where dual advanced therapy may be considered. 4. Contrast treatment targets in psoriasis and IBD, including PASI-based skin clearance versus clinical remission, endoscopic improvement and mucosal healing. 5. Identify practical approaches to vaccination and treatment onboarding for patients starting biologic or other advanced systemic therapies. đ§ Part 2 of 3 â stay tuned for Part 3 as the conversation moves into monitoring and treat-to-target across the skinâgut axis. #SkinAndJoints #Dermatology #Gastroenterology #IBD #CrohnsDisease #Psoriasis #SkinGutAxis #Biologics #IL23 #IL17 #TNFInhibitors #InflammatoryDisease #PrecisionMedicine #MultidisciplinaryCare #MedicalEducation #HCPeducation đ§Źđ©șđ SUPPORTED BY AN IME GRANT FROM JnJ Johnson and Johnson. ABOUT Dr. Parbeer Grewal Dermatologist, Edmonton, AB Dr. Parbeer Grewal completed his Bachelor of Science undergraduate degree at the University of Alberta with a specialization in Psychology and graduated with distinction. He completed his Doctorate of Medicine degree at the University of Alberta and graduated with Special Training in Research. He completed dermatology training at the University of Alberta and became a Fellow of the Royal College of Physicians and Surgeons of Canada and a board-certified Fellow of the American Academy of Dermatology. Dr. Grewal is an Associate Clinical Professor within the University of Albertaâs Faculty of Medicine - Dermatology. In addition to working at Rejuvenation, he is a consulting physician for the University of Alberta Hospital, the Royal Alexandra Hospital, the Grey Nuns Hospital and the Misericordia Hospital. Dr. Grewal has participated in over 60 clinical research trials for a multitude of dermatology conditions and medications. In addition, Dr. Grewal serves on multiple national and international scientific advisory boards, is a distinguished peer reviewer for medical journals and has published both journal articles and book chapters in dermatology. He has specific interests in psoriasis, acne, eczema, warts, skin cancers, rashes and moles. He offers a wide range of topical and systemic therapy along with surgical and aesthetic services. ABOUT Dr. Jesse Siffledeen, MD, FRCPC Gastroenterology, Edmonton, AB Dr. Siffledeen is a clinical professor in the Division of Gastroenterology at the University of Alberta. He is also currently the past-president of the Alberta Society of Gastroenterology. He has established a large clinical IBD practice in Edmonton and is the director of the South Edmonton Gastroenterology Research Unit, serving as principal investigator and collaborator on several IBD-related clinical trials for over 20 years. He is an active collaborator in the Edmonton IBD research community and as a member of the Canadian IBD research consortium. Dr. Siffledeen completed his Gastroenterology studies at the University of Alberta in 2010 and inflammatory bowel disease research/Masterâs degree at the University of Oxford in 2011. đ»www.skinandjoints.ca âïžinfo@skinandjoints.ca
đïž Beyond Skin Deep & Gut Feelings â Part 2: When the Gut and Skin Share the Treatment Plan
One patient. Two organ systems. And suddenly, choosing a biologic gets a whole lot more interesting. đ
In Part 2 of our Derm Ă GI crossover, podcast Faculty members dermatologist Dr. Perry Grewal and gastroenterologist Dr. Jesse Siffledeen move from diagnosis into the real-world treatment decisions that happen when psoriasis and inflammatory bowel disease collide.
PRO-TIPS COVERED: How do you practically choose one therapy when youâre treating two inflammatory diseases? When might suspected IBD steer a dermatologist away from an IL-17 inhibitor? What happens when the dose needed for Crohnâs disease doesnât match the dose used for psoriasis? And when one drug isnât enough, is dual advanced therapy the next frontierâor an insurance headache waiting to happen? đ
The conversation also digs into the very different therapeutic ceilings in dermatology and gastroenterology, including emerging data in perianal Crohnâs disease, the challenge of achieving true mucosal healing, and why GI may still be chasing remission rates that dermatology has already learned to expect from modern psoriasis therapy.
It gets practical: Who owns the prescription? Who takes the lead when one organ system flares? How much communication is really needed between specialists? And where do vaccinations fit when advanced therapy needs to start quickly?
From IL-23s vs IL-17s to biologic dosing, multidisciplinary care, vaccine timing and the occasional therapeutic turf war, this is where âshared careâ leaves the PowerPoint slide and enters actual clinical practice. đ§©
đŻ Learning Objectives
After listening to this episode, participants should be able to:
đ§ Part 2 of 3 â stay tuned for Part 3 as the conversation moves into monitoring and treat-to-target across the skinâgut axis.
#SkinAndJoints #Dermatology #Gastroenterology #IBD #CrohnsDisease #Psoriasis #SkinGutAxis #Biologics #IL23 #IL17 #TNFInhibitors #InflammatoryDisease #PrecisionMedicine #MultidisciplinaryCare #MedicalEducation #HCPeducation đ§Źđ©șđ
SUPPORTED BY AN IME GRANT FROM JnJ Johnson and Johnson.
ABOUT Dr. Parbeer Grewal
Dermatologist, Edmonton, AB
Dr. Parbeer Grewal completed his Bachelor of Science undergraduate degree at the University of Alberta with a specialization in Psychology and graduated with distinction. He completed his Doctorate of Medicine degree at the University of Alberta and graduated with Special Training in Research. He completed dermatology training at the University of Alberta and became a Fellow of the Royal College of Physicians and Surgeons of Canada and a board-certified Fellow of the American Academy of Dermatology.
Dr. Grewal is an Associate Clinical Professor within the University of Albertaâs Faculty of Medicine - Dermatology. In addition to working at Rejuvenation, he is a consulting physician for the University of Alberta Hospital, the Royal Alexandra Hospital, the Grey Nuns Hospital and the Misericordia Hospital. Dr. Grewal has participated in over 60 clinical research trials for a multitude of dermatology conditions and medications. In addition, Dr. Grewal serves on multiple national and international scientific advisory boards, is a distinguished peer reviewer for medical journals and has published both journal articles and book chapters in dermatology.
He has specific interests in psoriasis, acne, eczema, warts, skin cancers, rashes and moles. He offers a wide range of topical and systemic therapy along with surgical and aesthetic services.
ABOUT Dr. Jesse Siffledeen, MD, FRCPC
Gastroenterology, Edmonton, AB
Dr. Siffledeen is a clinical professor in the Division of Gastroenterology at the University of Alberta. He is also currently the past-president of the Alberta Society of Gastroenterology. He has established a large clinical IBD practice in Edmonton and is the director of the South Edmonton Gastroenterology Research Unit, serving as principal investigator and collaborator on several IBD-related clinical trials for over 20 years. He is an active collaborator in the Edmonton IBD research community and as a member of the Canadian IBD research consortium.
Dr. Siffledeen completed his Gastroenterology studies at the University of Alberta in 2010 and inflammatory bowel disease research/Masterâs degree at the University of Oxford in 2011.
đ»www.skinandjoints.ca
âïžinfo@skinandjoints.ca